恒瑞医药瑞维鲁胺片临床试验获批

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of Ruvelamib tablets in combination with HS-20093 injection for prostate cancer treatment [1] Company Summary - Ruvelamib tablets are a second-generation AR inhibitor, demonstrating stronger AR inhibition compared to first-generation inhibitors, with no agonistic effects [1] - Ruvelamib tablets were approved for market launch in 2022 for the treatment of high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1]